Methoxphenidine

From PsychonautWiki
(Redirected from MXP)
Jump to: navigation, search
Summary sheet: Methoxphenidine
Methoxphenidine
Molecular structure of methoxphenidine
Methoxphenidine.svg
Chemical Nomenclature
Common names Methoxphenidine, MXP
Substitutive name 2-MeO-Diphenidine
Systematic name (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
Class Membership
Psychoactive class Dissociative
Chemical class Piperidine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 30 - 50 mg
Light 50 - 75 mg
Common 75 - 120 mg
Strong 120 - 150 mg
Duration
Total 6 - 8 hours
Onset 30 - 60 minutes
After effects 1 - 3 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Methoxphenidine (1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine or MXP) is a dissociative hallucinogenic compound of the diarylethylamine chemical class that has been sold online as a designer drug.[1][2] It induces a state referred to as "dissociative anesthesia" and has similar effects to that of the arylcyclohexylamine and morphinan classes of dissociatives.

This compound was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.[3] Shortly after the 2013 UK ban on arylcyclohexylamines, methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form.[4] It is often marketed as a replacement for MXE despite many users reporting it as qualitatively different in its effects.

Chemistry

Generic structure of a piperdine molecule.

Methoxphenidine, or 2-MeO-Diphenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. The terminal amino group of the phenethylamine chain is incorporated into a piperidine ring. Hence, methoxphenidine belongs to the piperidine dissociative class of compounds. Methoxphenidine is structurally analogous to Diphenidine, containing an additional 2-methoxy CH3O- substitution.

Pharmacology

Further information: NMDA receptor antagonist

MXP acts as an NMDA receptor antagonist.[5] NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”

Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXP has very little history of human usage. Anecdotal evidence from people who have tried MXP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of MXP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MXP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Prominent examples include PCP and its analogs 3-MeO-PCP, MXE, and the diarylethylamine dissociatives like diphenidine or ephenidine. There is also evidence that suggests that combining these two increases their neurotoxicity.[citation needed] Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[6]
  • China - As of October 2015 MXP is a controlled substance in China.[7]
  • Sweden - MXP is also banned in Sweden.[8]
  • Canada - As of March 2016, MT-45 and its analogues, one of which being Methoxphenidine, are Schedule I controlled substances.[9] Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
  • Italy - MXP is banned in Italy according to the Table of Drugs since 2016. [10]

See also

External links

References

  1. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24678061
  2. "Word of mouse": indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25715070
  3. 1,2-diarylethylamines for treatment of neurotoxic injury | https://www.google.com/patents/EP0346791B1
  4. Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers | http://onlinelibrary.wiley.com/doi/10.1002/dta.1800/abstract
  5. MXP Patent | http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=0346791&KC=&FT=E&locale=en_EP
  6. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  7. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  8. Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/mars/fler-amnen-foreslas-bli-klassade-som-narkotika-eller-halsofarlig-vara/
  9. Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php
  10. http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf